Compare Gilead Sciences, Inc. (GILD) vs Opendoor Technologies Inc (OPEN) Price & Performance

Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.

Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.

Opendoor Technologies (OPEN) trades at $4.65, up 2.2% today, with a neutral technical signal and bearish moving averages. The company reported a net loss of $1.30 billion on $4.37 billion revenue in 2025, with a negative net margin of -35.25%. Recent news highlights a 7-11% stock jump amid iBuyer rallies and the upcoming Q2 2026 earnings report on August 4, 2026, while the company shutters its India operations to focus on AI-driven efficiency.

The outlook remains challenged by persistent losses and high debt, but cost discipline and margin improvements under the new CEO offer a potential path to EBITDA break-even. Key risks include housing market volatility and interest rate sensitivity, while analyst consensus is cautious with 65% hold ratings. The stock's low P/S ratio of 1 suggests undervaluation relative to peers if execution improves.